John Diaz, MD
Gynecologic Oncology · Miami, FLNPI 1578719167
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AstraZeneca at 55.8% of the total. Reporting peaked in 2020 at $22,225 and has fallen 84.5% since, to $3,436 in 2025.
Across 250 payments — averaging $349.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$49K
- Intuitive Surgical$15K
- Merck$8K
- Medtronic$3K
- Eisai Inc.$3K
- GSK$2K
- plus $8K from 18 others
Across 170 payments — averaging $20,996 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3M
- Seagen Inc.$294K
- AbbVie$139K
- AstraZeneca$124K
- Trillium Therapeutics USA, LLC$22K
- Astrazeneca UK Limited$17K
- plus $5K from 1 others
What the payments were for
- Consulting fees$12,77315%
- Speaking & faculty fees$51,65059%
- Travel & lodging$8,48310%
- Food & beverage$11,81414%
- Education$2,6153%
- Gifts$630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $48,755 |
| Intuitive Surgical | 112 | $14,855 |
| Merck | 11 | $7,655 |
| Medtronic(2 entities) | 6 | $3,272 |
| Eisai Inc. | 4 | $2,933 |
| GSK | 12 | $2,130 |
| Seagen Inc. | 5 | $1,933 |
| Karyopharm Therapeutics Inc. | 2 | $1,672 |
| Linvatec Corporation | 1 | $1,000 |
| Conmed Corporation | 15 | $897 |
| AbbVie | 14 | $558 |
| Johnson & Johnson | 10 | $477 |
| Hologic Sales And Service, LLC | 7 | $427 |
| On Target Laboratories, Inc | 4 | $160 |
| Astellas Pharma US Inc | 3 | $135 |
| Biom'up France SAS | 1 | $132 |
| Covidien LP | 1 | $100 |
| Genmab U.S., Inc. | 1 | $94 |
| Procept Biorobotics Corporation | 1 | $82 |
| Sumitomo Pharma America, Inc. | 2 | $53 |
| Myriad Genetic Laboratories, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$45,534
- Da Vinci Surgical System$11,945
- KEYTRUDA$7,253
- LENVIMA$2,889
- ZEJULA$1,950
- TIVDAK$1,819
- XPOVIO$1,610
- AIRSEAL$1,138
- Orilissa$229
- ACESSA PROVU SYSTEM$138
- HemoBlast Bellows$132
- MyCareLink$130
- Elahere$126
- LigaSure$125
- Valleylab$100
How this compares
$87,398 in reported general payments places this provider in the 85th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Miami
- Ricardo EstapeMiami$457K
- Troy GatcliffeMiami$172K
- Jean-Marie StephanMiami$40K
- Eric SchroederMiami$10K
- Matthew SchlumbrechtMiami$9K
- Bradley MonkWest Palm Beach$2.5M
- Martin MartinoJacksonville$957K
- Brian SlomovitzFort Lauderdale$519K
- Robert HollowayOrlando$432K
- Shelly SewardOrlando$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.